Pfizer Inc (PFE.N)
* Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
* Says amendment to increase the purchase price of the acquisition to $40 million
* No new or unexpected safety findings for Tofacitinib were observed in study
* Pfizer and Western Oncolytics announce immuno-oncology research collaboration to investigate novel oncolytic virus technology
LONDON Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes.
* New drug Tagrisso sold better-than-expected $92 mln in Q2 (Adds CEO comments on upcoming clinical data and M&A)
LONDON, July 28 AstraZeneca declined to comment on Thursday on whether the drugmaker could become a takeover target once more, two years after it saw off a bid from Pfizer.
July 27 Eli Lilly & Co will likely step up the pace of making deals with other drugmakers while aggressively developing new drugs on its own, the company's newly appointed chief executive said on Wednesday.
FRANKFURT Bayer , the German drugmaker trying to acquire U.S. seed company Monsanto , surpassed second-quarter earnings expectations and raised its guidance for the year as strong gains in stroke prevention pill Xarelto offset sluggish farming pesticides markets.
* Shares seen up 0.7 pct in premarket trades (Adds details on Xarelto, Eylea, Crop Chemicals unit, background on Monsanto)
|Johnson & Johnson (JNJ.N)||$125.23||+0.77|
|Novartis AG (NOVN.S)||CHF80.30||0.00|
|Merck & Co., Inc. (MRK.N)||$58.66||+0.23|
|Roche Holding Ltd. (ROG.S)||CHF247.50||+2.00|
|Roche Holding Ltd. (RO.S)||CHF249.60||+1.80|
|Abbott Laboratories (ABT.N)||$44.75||+0.30|
|Bayer AG (BAYGn.DE)||€96.22||+1.91|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€76.15||-0.14|
|AstraZeneca plc (AZN.L)||5,048.00p||+21.00|
Earnings vs. Estimates
Analyst Research Reports
Provider : Thomson Reuters Stock Report
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Wright Reports
"The Economy Matters" Report for PFE: the economy's impact on PFE's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider : MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.